Mettler F A, Christie J H, Crow N E, Garcia J F, Wicks J D, Bartow S A
Cancer. 1982 Sep 1;50(5):909-11. doi: 10.1002/1097-0142(19820901)50:5<909::aid-cncr2820500518>3.0.co;2-d.
One hundred-five patients with ovarian carcinoma had radionuclide liver/spleen scanning done at the time of staging. Of the 105 initial scans, eight were interpreted as having hepatocellular dysfunction. Seven of these eight had abnormal liver function studies. One patient had a hepatic cyst but had elevated liver function studies. Six patients demonstrated hepatic metastases (at the time of staging). All but one of these occurred in Stage IV tumors of epithelial origin (adenocarcinoma). No hepatic metastases were demonstrated in Stage I or II tumors, and only one Stage III epithelial carcinoma had hepatic metastases. Three patients developed hepatic metastases during the course of treatment. All nine patients with hepatic metastases had abnormal concurrent liver function studies. It is suggested that screening for liver metastases in patients with ovarian carcinoma is of limited value in patients with normal liver function studies.
105例卵巢癌患者在分期时进行了放射性核素肝/脾扫描。在这105次初始扫描中，8次被解读为存在肝细胞功能障碍。这8例中有7例肝功能检查异常。1例患者有肝囊肿，但肝功能检查结果升高。6例患者（在分期时）显示有肝转移。除1例之外，所有这些均发生在上皮源性（腺癌）的IV期肿瘤中。I期或II期肿瘤未显示有肝转移，只有1例III期上皮癌有肝转移。3例患者在治疗过程中出现肝转移。所有9例有肝转移的患者同时肝功能检查均异常。提示对于肝功能检查正常的卵巢癌患者，筛查肝转移的价值有限。
